BIIB Biogen Inc.

227.72
+1.66  (+1%)
Previous Close 226.06
Open 226.23
Price To Book 3.24
Market Cap 42,002,320,483
Shares 184,447,218
Volume 1,380,284
Short Ratio
Av. Daily Volume 1,514,544
Stock charts supplied by TradingView

NewsSee all news

  1. NURTURE study shows pre-symptomatic Spinal Muscular Atrophy (SMA) infants treated with SPINRAZA™ (nusinersen injection) attained positive results

    Treatment with SPINRAZA™ resulted in survival of 100 percent of infants and none requiring permanent ventilation Recently published outcomes include motor milestones achieved in 100 percent of infants sitting without

  2. Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders

    Treatment with SPINRAZA resulted in survival of 100 percent of infants, with none requiring permanent ventilationMotor milestones achieved included 100 percent of participants sitting without support and 88 percent

  3. Biogen Announces Leadership Update

    Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief Medical Officer Dr. Alphonse Galdes appointed Executive Vice President, Pharmaceutical Operations and Technology

  4. Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding

    Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before conception and/or during

  5. Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

    DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefitsLong-term data from the SHINE

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 data due 2H 2020.
BIIB112
X-linked Retinitis Pigmentosa
Phase 3 data due 2H 2020.
BIIB111
Choroideremia
Phase 2 data due 2H 2020.
BIIB054
Parkinson's disease
Phase 2 data due 1H 2020.
Natalizumab - OPUS
Epilepsy
Phase 3 commencement of enrollment announced September 4, 2018.
BIIB093
Large hemispheric infarction
Phase 3 ready to be initiated. Acquired from Remedy Pharmaceuticals May 15, 2017.
CIRARA (intravenous glyburide)
Ischemic stroke
Phase 2 data due 2H 2019.
BIIB092 - Anti Tau
Progressive supranuclear palsy (PSP)
Phase 3 trial discontinued due to unfavorable risk-benefit ratio.
Elenbecestat (E2609) - (MissionAD2)
Alzheimer’s disease
Phase 3 trial discontinued due to futility - unlikely to meet primary endpoint upon completion - March 21, 2019.
Aducanumab (Aβ mAb) - EMERGE
Alzheimer’s disease
Phase 3 trial to be initiated later in 2019.
BIIB074 (Nav1.7 inhibitor)
Trigeminal Neuralgia
Phase 3 trial discontinued due to unfavorable risk-benefit ratio.
Elenbecestat (E2609) - (MissionAD1)
Alzheimer’s disease
Phase 2b data due mid-2020.
Opicinumab (AFFINITY)
Multiple sclerosis (MS)
Phase 3 trial discontinued due to futility - unlikely to meet primary endpoint upon completion - March 21, 2019.
Aducanumab (Aβ mAb) - ENGAGE
Alzheimer’s disease
Phase 2b data released February 8, 2018 - primary endpoint not met.
Natalizumab (α4-integrin inhibitor)
Acute ischemic stroke
Phase 2 data released September 2018 - primary endpoint not met.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Painful Lumbosacral Radiculopathy (PLSR)
Phase 2 topline data showed no statistically significant treatment effect for primary and secondary endpoints - 1Q 2016.
Raxatrigine - BIIB074 (Nav1.7 inhibitor)
Erythromelagia
Phase 2 data due by end of 2019.
BIIB059 (anti-BDCA2)
Lupus
Phase 2b data released October 23, 2018 - primary endpoint not met.
Dapirolizumab pegol (anti-CD40L)
Lupus
Phase 3 initiation announced March 22. 2019.
BAN2401
Alzheimer’s disease
Phase 2b trial initiated September 2018.
BG00011 (STX-100)
Idiopathic pulmonary fibrosis (IPF)
Phase 1/2 data released June 8, 2017.
XLRS Gene Therapy
X-linked retinoschisis (XLRS)
NDA filing announced December 17, 2018. NDA acceptance announced February 25, 2019. PDUFA estimate December 24, 2019.
Diroximel fumarate (BIIB098)
Multiple sclerosis (MS)
Phase 3 data due 2021.
IONIS-SOD1Rx / BIIB067
Amyotrophic lateral sclerosis (ALS)
Phase 3b trial initiation announced January 3, 2019.
Natalizumab - NOVA
Multiple sclerosis (MS)
Phase 2b data due late-2020.
BIIB104
Cognitive Impairment Associated With Schizophrenia (CIAS)
Phase 2 data due late-2020.
TMS-007
Stroke
Phase 2 data due late-2020.
BIIB074 (Nav1.7 inhibitor)
Small Fibre Neuropathy
Phase 2/3 initiation announced September 18, 2019.
SPINRAZA - DEVOTE
Spinal muscular atrophy (SMA)

Latest News

  1. NURTURE study shows pre-symptomatic Spinal Muscular Atrophy (SMA) infants treated with SPINRAZA™ (nusinersen injection) attained positive results

    Treatment with SPINRAZA™ resulted in survival of 100 percent of infants and none requiring permanent ventilation Recently published outcomes include motor milestones achieved in 100 percent of infants sitting without

  2. Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders

    Treatment with SPINRAZA resulted in survival of 100 percent of infants, with none requiring permanent ventilationMotor milestones achieved included 100 percent of participants sitting without support and 88 percent

  3. Biogen Announces Leadership Update

    Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief Medical Officer Dr. Alphonse Galdes appointed Executive Vice President, Pharmaceutical Operations and Technology

  4. Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding

    Positive opinion is supported by data from more than 1,000 real-world pregnancy outcomes Data indicate no increased risk of major congenital anomalies after exposure to interferon beta before conception and/or during

  5. Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients

    DEVOTE trial to evaluate safety and even greater efficacy of a higher dose of SPINRAZA in the treatment of SMA; well-established safety profile supports exploration of potential benefitsLong-term data from the SHINE

  6. Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

    CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced that it has been ranked the #1 biotechnology company on the Dow Jones Sustainability World Index (DJSI World) for the

  7. Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease

    WOODCLIFF LAKE, N.J., Sept. 13, 2019 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ:BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel

  8. New Research Demonstrate Biogen's Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum

    Data highlight benefits of TYSABRI® (natalizumab) treatment in early multiple sclerosis for achieving NEDA (no evidence of disease activity) and improving disability and cognitionAn analysis of data from the TYSABRI

  9. New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years

    TECFIDERA consistently maintained low levels of disease activity with no increased risk in adverse events over a decade of treatmentLatest interim data from Phase 3 EVOLVE-MS-1 trial show Biogen and Alkermes'